Julien Hadoux

Dr Julien Hadoux is a medical oncologist specialising in endocrine cancers within the Endocrine Oncology Unit at Gustave Roussy. Since 2026, he has been Head of the Endocrine Pathologies Committee. His clinical and scientific work focuses on the management of thyroid, neuroendocrine and adrenal cancers, with a particular interest in rare or refractory forms and in the development of innovative therapeutic strategies.

Dr Hadoux completed his medical and scientific training in the Paris region. He holds an MD in Medical Oncology from Université Paris Descartes and a PhD in Oncology from Université Paris-Saclay, conducted within an INSERM research unit focusing on the modelling of tumour stem cells. He also holds university diplomas in biostatistics and endocrine tumours.

Following his residency in medical oncology (2007–2012), he pursued an academic hospital career with a focus on translational research. He then served as Assistant Specialist at Gustave Roussy before being appointed Consultant in 2019. He currently leads a specialised clinical practice, coordinates national and international clinical trials, and is actively involved in structuring care pathways for rare endocrine cancers.

At the national level, he has served since 2021 as co-coordinator of the French network for refractory thyroid cancers (ENDOCAN-TUTHYREF), before becoming national coordinator of the ENDOCAN network in 2025, a network accredited by the French National Cancer Institute (INCa) and dedicated to rare endocrine cancers. He is a member of several scientific societies and cooperative groups, including the Groupe d’étude des tumeurs endocrines (GTE) and the International Thyroid Oncology Group. Within the European Society for Medical Oncology (ESMO), he is involved in the endocrine track and guidelines groups.

His research focuses on the identification of prognostic and predictive biomarkers, the evaluation of novel targeted therapies and immunotherapies, and the optimisation of therapeutic strategies in advanced endocrine cancers. He serves as principal investigator or coordinator of several academic trials and translational research studies funded in particular by the French National Cancer Institute, the American Thyroid Association in partnership with ThyCa: Thyroid Cancer Survivors’ Association, the French National Research Agency, as well as through industrial collaborations with IQVIA, Eli Lilly and Company, and Amgen.

Author or co-author of more than 120 international scientific publications (H-index 29), he actively contributes to clinical and translational research in endocrine cancers and to improving care pathways for these rare diseases.